A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806) Article

cited authors

  • Alexander, Brian M; Wang, Meihua; Yung, WK Alfred; Fine, Howard A; Donahue, Bernadine A; Tremont, Ivo W; Richards, Ray S; Kerlin, Kevin J; Hartford, Alan C; Curran, Walter J; Mehta, Minesh P

fiu authors

publication date

  • January 1, 2013

keywords

  • ADULTS
  • ANGIOGENESIS
  • Angiogenesis inhibitor
  • Clinical Neurology
  • Clinical trial
  • Controlled
  • ENDOTHELIAL GROWTH-FACTOR
  • EXPRESSION
  • Glioblastoma
  • HIGH-GRADE GLIOMAS
  • IRINOTECAN
  • Life Sciences & Biomedicine
  • MULTIFORME
  • Neurosciences & Neurology
  • Oncology
  • RECURRENT GLIOBLASTOMA
  • Radiation therapy
  • Science & Technology
  • TEMOZOLOMIDE
  • TRIAL DESIGN
  • Thalidomide

Digital Object Identifier (DOI)

start page

  • 33

end page

  • 39

volume

  • 111

issue

  • 1